To see the other types of publications on this topic, follow the link: Lactobacillus reuteri DSM 17938 derivatives.
Journal articles on the topic 'Lactobacillus reuteri DSM 17938 derivatives'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Lactobacillus reuteri DSM 17938 derivatives.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Knysh, O. V., S. A. Kolpak, M. S. Pogorila, and Ye M. Babych. "ADHESIVE PROPERTIES OF BACTERIA UNDER THE INFLUENCE OF BIFIDOBACTERIUM BIFIDUM 1 AND LACTOBACILLUS REUTERI DSM 17938I CELL-FREE EXTRACTS." Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 20, no. 2 (2020): 129–34. http://dx.doi.org/10.31718/2077-1096.20.2.129.
Full textAbstract:
Increasing in the adhesive potential of probiotic bacteria on the one hand and weakening the adhesive ability of the pathobionts on the other is a pathogenetically based approach in the fight against intestinal infectious diseases and intestinal dysbiosis. At present postbiotic products are considered as one of the most promising means of influencing the intestinal microbiota. The aim of the work was to study the effect of cell-free extracts containing derivatives of Bifidobacterium bifidum 1 and Lactobacillus reuteri DSM 17938 on the adhesive properties of probiotic (L. reuteri DSM 17938 and B. bifidum 1) and opportunistic bacteria (Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922). Four cell-free extracts were investigated: L – obtained from the L. reuteri disintegrate; ML – obtained from the L. reuteri culture, cultivated in its own disintegrate; B – obtained from the B. bifidum disintegrate; MB – obtained from the B. bifidum culture, cultivated in its own disintegrate. The effect of cell-free extracts on the adhesive properties of microorganisms was studied by using Brilis method. ML, MB, and B extracts were found to be able to significantly increase the adhesive potential of B. bifidum and L. reuteri. Under their influence adhesion index calculated for bifidobacteria increased by 41.1 % (ML), 41.5 % (MB) and 50.6 % (B), and the microorganism adhesion index calculated for lactobacilli increased by 30.77 % (ML), 44.45 % (MB) and 44.97 % (B). Both studied probiotic bacteria moved up from the category of «moderately adhesive» into the category of «strongly adhesive» with microorganism adhesion index > 4.0. Lactobacilli also became «strongly adhesive» under the influence of L extract, while microorganism adhesion index increased by 37.9 %. Among the studied extracts, only L extract caused a significant increase in the adhesion index of the S. aureus test culture. The other extracts caused minor changes in the adhesive potential of the test cultures. Under their influence, there was a tendency to increase or decrease the adhesive ability of bacteria. Under the influence of MB extract, the S. aureus test culture passed from the «strongly adhesive» category to the «moderately adhesive» category, and the E. coli test culture transferred from the «moderately adhesive» category to the «weakly adhesive» category. The data obtained are of great importance when developing new metabiotics based on the B. bifidum 1 and L reuteri DSM 17938 probiotic strains derivatives.
2
Knysh, O.V., and A.V. Martynov. "Potentiation of the antimicrobial effect of Lactobacillus reuteri DSM 17938 cell-free extracts by ascorbic acid." Medicni perspektivi 25, no. 1 (2020): 17–24. https://doi.org/10.5281/zenodo.3953882.
Full textAbstract:
The purpose of this study was to evaluate the effect of supplementing the culture medium with ascorbic acid on the antimicrobial properties of Lactobacillus reuteri cell-free extracts (CFEs). CFEs were prepared using commercial strain L. reuteri DSM 17938 by culturing lactobacilli in its own disintegrated cell suspension (DCS) supplemented with ascorbic acid in sub-inhibitory (5 mg/ml, CFE<sub>5</sub>) or minimal inhibitory concentration (20 mg/ml, CFE<sub>20</sub>) and without supplementation (CFE<sub>0</sub>). Staphylococcus aureus AТСС 25923, Escherichia coli AТСС 25922 reference strains and Pseudomonas aeruginosa extensively drug resistant (XDR) clinical isolate were used as indicator cultures. Screening of the inhibitory properties of the studied CFEs and elucidation of the nature of inhibitory products were done using modified Micro scale Optical Density Assay (MODA). The inhibition indices (InhI) were calculated for the studied CFEs and ascorbic acid of appropriate concentrations. CFEs were subjected to HPLC-analysis. CFE<sub>5</sub> and CFE<sub>20</sub> showed significantly higher antimicrobial activity toward to indicator cultures than CFE<sub>0</sub>. InhI calculated for extracts CFE<sub>5</sub> and CFE<sub>20</sub> mainly exceeded the sum of the corresponding indicators calculated for CFE<sub>0</sub> and ascorbic acid (АА) of appropriate concentrations: InhI CFE<sub>5</sub> ≥ InhI CFE<sub>0 </sub>+ InhI AA<sub>5</sub>; InhI CFE<sub>20</sub> > InhI CFE<sub>0 </sub>+ InhI AA<sub>20. </sub>Acidic metabolic products have made the greatest contribution to the antimicrobial effect of the studied CFEs. HPLC-nalysis showed that the modified ascorbic acid was the substance found in CFE<sub>20</sub> in the greatest quantity. The revealed effect of potentiation of antimicrobial activity of CFEs by ascorbic acid should be taken into account when developing new biotechnological products based on derivatives of L. reuteri DSM 17938.
3
Knysh, O. V., and Yu V. Nikitchenko. "IN VITRO ANTI-RADICAL ACTIVITY OF BIFIDOBACTERIUM BIFIDUM AND LACTOBACILLUS REUTERI CELL-FREE EXTRACTS." Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 20, no. 1 (2020): 140–44. http://dx.doi.org/10.31718/2077-1096.20.1.140.
Full textAbstract:
Probiotic microorganisms are known to be able to exhibit antioxidant activity. Most of beneficial probiotics effects are due to the action of their derivatives (structural components and metabolites). The aim of the work was to investigate the antiradical activity of cell-free extracts containing bacterial derivatives of Bifidobacterium bifidum 1 and Lactobacillus reuteri DSM 17938 probiotic strains, by their hydroxyl radical scavenging activity in the model system of their generation. Cell-free extracts were obtained from disintegrators and cultures of probiotic bacteria cultured in the disintegrators of their own cells. A metabiotic HYLAK FORTE was chosen as the reference drug. At a concentration 20% vol. in the incubation medium the hydroxyl radical scavenging by L. reuteri cell-free extracts was at a level of 75–90 %, and the hydroxyl radical scavenging by B. bifidum cell-free extracts was at a level of 50–60%. The metabiotic provided the same level of the hydroxyl radical scavenging activity when its content in the incubation medium was lower in 1.5 – 2.5 times. Extracts obtained from disintegrators showed a more pronounced antiradical activity than extracts from probiotic cultures. Based on the weight of the dry residue, concentrations for 50% hydroxyl radical scavenging (ІС50) by extracts and metabiotic were calculated. According to this indicator, L. reuteri extract obtained from disintegrate was the most effective (IC50 = 1.57 mg/ml). Other investigated derivative-containing products were arranged in decreasing order of antiradical activity as follows: B. bifidum extract from disintegrate (IC50 = 1, 64 mg/ml) > B. bifidum extract from culture (IC50 = 1, 75 mg/ml) > L. reuteri extract from culture (IC50 = 1, 86 mg/ml) > HYLAK FORTE (IC50 = 11, 03 mg/ml). Thus, all the studied extracts showed antiradical activity with respect to the most reactive hydroxyl radical. The obtained results encourage further study of the antioxidant properties of L. reuteri and B. bifidum cell-free extracts in order to elucidate the mechanisms of their biological activity and justify the appropriateness of their therapeutic use.
4
Knysh, O. V., M. S. Pogorila, and Y. V. Voyda. "In vitro immunomodulatory effect of Bifidobacterium bifidum and Lactobacillus reuteri cell free extracts." Regulatory Mechanisms in Biosystems 11, no. 1 (2020): 93–97. http://dx.doi.org/10.15421/022013.
Full textAbstract:
Recent studies have shown that alterations of the immune response in the gastrointestinal mucosa are key components of the mechanism of the probiotic action of beneficial bacteria. Most of the beneficial effects of probiotics are due to the action of their structural components and metabolites. Macrophages are first-line defense cells of the immune system, which not only participate in the detection, phagocytosis and destruction of harmful microorganisms, but also determine the nature of the subsequent immune response by presenting antigens to T-cells and initiating inflammation by releasing cytokines. We researched the effect of two types of cell-free extracts (CFEs) containing probiotic derivatives (structural components and metabolites of bacteria) Bifidobacterium bifidum 1 (BbCFE) and Lactobacillus reuteri DSM 17938 (LrCFE) on the activity of mouse peritoneal macrophages and on the ability of peripheral human blood mononuclear cells to produce cytokines. CFEs were obtained by culturing probiotics in their own disintegrates and then removing cells and cell debris by centrifugation and filtration. Peritoneal macrophages were isolated from mice. Some of them were infected in vitro by Salmonella thyphimurium. Uninfected and infected macrophages were incubated in culture medium containing (30% vol) or not containing CFEs at 37 °С in a microaerobic atmosphere (5% СО2) for 18 hours. After incubation, peritoneal macrophages were lysed. The obtained suspensions were centrifuged and supernatants were carefully collected. Macrophages activity was assessed by the nitrites level, superoxide dismutase (SOD), lactate dehydrogenase (LDH) activity and antiinflammatory cytokines levels in supernatants using spectrophotometric method. Peripheral mononuclear cells were isolated from the blood of healthy volunteers. The ability of peripheral mononuclear blood cells to produce antiinflammatory cytokines was evaluated after cell stimulation with lipopolysaccharide (LPS) and incubation with or without CFEs. Cytokine levels in supernatants were determined using enzyme-linked immunosorbent assay (ELISA). After infection with S. thyphimurium in macrophages, nitrite levels increased 5.5-fold, SOD activity 4.8-fold, and LDH 2-fold. Both studied CFEs exerted a similar effect on the macrophages’ activity. Addition of BbCFE to the incubation medium of infected macrophages resulted in a 4-fold decrease in nitrite levels, and the addition of LrCFE was accompanied by a decrease in nitrite levels to levels in intact cells. Under the influence of both CFEs, the activity of SOD and LDH was significantly reduced and did not differ significantly from the activity of these enzymes in intact cells. BbCFE and LrCFE did not have a significant effect on nitrite levels, SOD and LDH activity in intact macrophages. Under the influence of BbCFE, there was a 2-fold decrease in the production of TNF, a 2-fold increase in IL10 production, and a 30% increase in IL6 production by mononuclear cells. LrCFE caused a decrease in TNF production by 26.7% and IL6 by 36%, and IL10 by 1.9 times. Thus, the studied CFEs normalized the nitrite levels in peritoneal macrophages infected with S. thyphymurium and infection-induced activation of SOD and LDH enzymes. This demonstrates their ability to modulate oxidative processes in macrophages. In addition, under the influence of the investigated CFEs, there was a decrease in the production of pro-inflammatory cytokines (TNFα and IL-6) and increased production of anti-inflammatory cytokine (IL-10) by human peripheral mononuclear cells. The results of the study indicate the ability of CFEs by influencing the functions of innate immunity cells to restrict the inflammatory response and oxidative stress. Based on this, CFEs can be considered as promising agents for the treatment of inflammatory diseases.
5
Faizullina, R. A., and S. E. Ukraintsev. "Role of Lactobacillus reuteri in human health." Voprosy detskoj dietologii 22, no. 4 (2024): 38–44. https://doi.org/10.20953/1727-5784-2024-4-38-44.
Full textAbstract:
The role that the gut microbiota plays in maintaining human health cannot be overemphasized. Numerous studies have shown that dysbiosis is associated with several pathological conditions. Some probiotic strains have proven to be effective both in improving the composition of the gut microbiota and in preventing or correcting certain pathological conditions. This review presents data on different strains of Lactobacillus reuteri, primarily an updated information on the efficacy of the probiotic strain L. reuteri DSM 17938 in the treatment and prevention of various human diseases. Key words: Lactobacillus reuteri, Lactobacillus reuteri DSM 17938, probiotics, gut microbiota, colic, constipation, regurgitation
6
Kryvopustov, S. P. "Lactobacillus reuteri DSM 17938 and vitamin D3 in common clinical problems of infants." Modern pediatrics. Ukraine, no. 1(113) (February 19, 2021): 68–72. http://dx.doi.org/10.15574/sp.2021.113.68.
Full textAbstract:
Purpose — to demonstrate the clinical significance of Lactobacillus reuteri DSM 17938 and vitamin D3 in common clinical problems in infants. Materials and methods. Clinical cases in pediatrics of infancy in children with infant colic (G4), infant regurgitation (G1), functional constipation (G7) are presented. Some international recommendations regarding a preventive dose of vitamin D in the first year of a child' life are considered. Results. The behavior of an infant is often a concern for parents and is a reason for seeking medical help. In particular, it has been shown when acute crying of a child is associated with threatening conditions. The prevalence of functional gastrointestinal disorders and the importance of using the Rome IV criteria in practice are emphasized. Clinical examples of infant colic (G4), infant regurgitation (G1), functional constipation (G7) demonstrated the management of patients with the importance of counseling, showing the evidence base for the use of Lactobacillus reuteri DSM 17938 and vitamin D3. Works on the importance of vitamin D for the prevention of respiratory infections and its dosage are presented. Conclusions. For children in the first year of life with infant colic (G4), infant regurgitation (G1), functional constipation (G7), counseling is important, as well as the use of, in particular, Lactobacillus reuteri DSM 17938. Additional benefits are provided by the combined use of Lactobacillus reuteri DSM 17938 with vitamin D3, which is also discussed for the prevention of respiratory infections. Provided international recommendations for a daily preventive dose of 400 IU of vitamin D for infants. No conflict of interest was declared by the author. Key words: vitamin D, infants, respiratory infections, functional gastrointestinal disorders, Lactobacillus reuteri DSM 17938.
7
Pacheco, Beatriz. "O uso de Lactobacillus reuteri DSM 17938 na cólica infantil: um tratamento eficaz?" Revista da Associação Brasileira de Nutrição - RASBRAN 12, no. 4 (2022): 171–85. http://dx.doi.org/10.47320/rasbran.2021.2503.
Full textAbstract:
O objetivo do presente estudo é realizar uma revisão integrativa da literatura para verificar a segurança e eficácia do uso de Lactobacillus reuteri DSM 17938 no tratamento da cólica infantil. A busca científica foi feita nas bases de dados PubMed, Medline, Lilacs e nos metabuscadores Acessss e Tripdatabase, entre os meses maio e agosto de 2020. Após a aplicação dos critérios de inclusão e exclusão definidos, 11 artigos foram selecionados para compor o trabalho. A cerca dos resultados dos estudos, oito (72,7%) apresentaram desfechos positivos em relação a eficácia do Lactobacillus reuteri DSM 17938 na diminuição dos sintomas de cólica infantil. Em contrapartida, alguns autores não encontraram diferenças significativas nos marcadores estudados, outros não relataram nenhum desfecho, apenas detalharam o protocolo de intervenção. Ainda que a suplementação de Lactobacillus reuteri DSM 17938 tenha apresentado segurança e eficácia na maior parte dos estudos analisados, não há evidências suficientes para recomendar seu uso como uma estratégia generalizada de tratamento.
8
Kubota, Megumi, Kazuya Ito, Kazuhiko Tomimoto, et al. "Lactobacillus reuteri DSM 17938 and Magnesium Oxide in Children with Functional Chronic Constipation: A Double-Blind and Randomized Clinical Trial." Nutrients 12, no. 1 (2020): 225. http://dx.doi.org/10.3390/nu12010225.
Full textAbstract:
Objective: Chronic functional constipation is a frequent condition. The aim of the study was to evaluate the efficacy of the probiotic Lactobacillus (L.) reuteri DSM 17938 and magnesium oxide (MgO) for relieving chronic functional constipation in children. Study design: A prospective, double-blind, placebo-controlled, randomized, and parallel-group trial was conducted in five pediatric outpatient clinics in Japan. Sixty patients who were more than six months old and under six years of age with a diagnosis of functional constipation according to Rome IV criteria were randomly divided into three groups: group A (n = 20) received L. reuteri DSM 17938 and lactose hydrate as a placebo of MgO; group B (n = 19) received L. reuteri DSM 17938 and MgO; and group C (n = 21) received a placebo of L. reuteri DSM 17938 and MgO. Results: All three groups exhibited significant improvement in defecation frequency in the fourth week compared with the baseline condition (group A: p < 0.05; group B: p < 0.05; group C: p < 0.05). The MgO group and combination group showed a significant decrease in stool consistency, but the L. reuteri DSM 17938 group did not (group A: p = 0.079; group B: p < 0.05; group C: p < 0.05). MgO significantly suppressed the presence of the genus Dialister. Defecation frequency negatively correlated with the frequency of Clostridiales-belonging bacteria among the gut microbiome. Conclusions: L. rueteri DSM 17938 and MgO were both effective in the management of functional constipation in young children. MgO caused an imbalance in the gastrointestinal microbiome, which was not the case in the probiotic group.
9
Новикова, В. П., and Д. М. Магомедова. "PROBIOTIC PROPERTIES OF LACTOBACILLUS REUTERI (L. REUTERI) STRAINS." Children's medicine of the North-West 11, no. 3 (2023): 36–53. http://dx.doi.org/10.56871/cmn-w.2023.75.34.002.
Full textAbstract:
Статус «пробиотик» присваивается тем микроорганизмам, которые считаются безопасными и соответствуют определенным критериям. Lactobacillus reuteri DSM 17938 (L. reuteri) — хорошо изученная бактерия, способная колонизировать у людей различные участки тела. Штамм, который используется сегодня, L. reuteri DSM 17938, недавно переименованный в Limosilactobacillus reuteri (L. reuteri), является пробиотиком, хорошо идентифицированным по его благотворному влиянию на некоторые желудочно-кишечные заболевания. Пробиотический эффект L. reuteri обусловлен целым комплексом особенных свойств. L. reuteri способен влиять на биоразнообразие, состав и метаболическую функцию микробиоты кишечника, полости рта и влагалища. Эти эффекты в значительной степени штаммоспецифичны. Основной терапевтической мишенью воздействия L. reuteri являются младенческие колики. У младенцев, помимо купирования колик и модуляции кишечной микробиоты, L. reuteri способны усиливать барьерную функцию слизистой оболочки, которая необходима для блокирования проникновения внешних антигенов и токсинов. Литературные данные свидетельствуют об эффективности L. reuteri при острой водянистой диарее, против H. pylori и при других заболеваниях: атопическом дерматите, ожирении, при кариесе, расстройствах аутистического спектра, аутоиммунных заболеваниях, в том числе воспалительных заболеваниях кишечника и системной красной волчанке и др. Безопасность и переносимость L. reuteri доказана многочисленными клиническими исследованиями. Существует несколько штаммов L. reuteri с различным происхождением, и многие из пробиотических функций L. reuteri зависят от штамма. И поэтому в будущем, возможно, может быть выгодно комбинировать различные штаммы L. reuteri, чтобы максимизировать их полезные эффекты. Probiotic status is given to microorganisms that are considered safe and meet certain criteria. Lactobacillus reuteri DSM 17938 (L. reuteri) is a well-studied bacterium that can colonize various parts of the body in humans. The strain in use today, L. reuteri DSM 17938, recently renamed Limosilactobacillus reuteri (L. reuteri), is a probiotic well identifi ed for its benefi cial eff ects on several gastrointestinal diseases. The probiotic eff ect of L. reuteri is due to a whole range of special properties. L. reuteri is able to infl uence the biodiversity, composition and metabolic function of the gut, oral and vaginal microbiota. These eff ects are largely strain-specifi c. The main therapeutic target of L. reuteri is infantile colic. In infants, in addition to relieving colic and modulating the intestinal microbiota, L. reuteri is able to enhance the mucosal barrier function, which is necessary to block the entry of external antigens and toxins. Literature data indicate the eff ectiveness of L. reuteri in acute watery diarrhea, against H. pylori and other diseases: atopic dermatitis, obesity, caries, autism spectrum disorders, autoimmune diseases, incl. infl ammatory bowel disease and systemic lupus erythematosus, etc. The safety and tolerability of L. reuteri has been proven by numerous clinical studies. There are several strains of L. reuteri with different origins and many of the probiotic functions of L. reuteri are strain dependent. Therefore, in the future, it may be advantageous to combine diff erent strains of L. reuteri in order to maximize their benefi cial eff ects.
10
Frerejacques, Marie, Camille Rousselle, Loüen Gauthier, et al. "Human Skin Bacterial Community Response to Probiotic (Lactobacillus reuteri DSM 17938) Introduction." Microorganisms 8, no. 8 (2020): 1223. http://dx.doi.org/10.3390/microorganisms8081223.
Full textAbstract:
The introduction of a strain or consortium has often been considered as a potential solution to restore microbial ecosystems. Extensive research on the skin microbiota has led to the development of probiotic products (with live bacterial strains) that are likely to treat dysbiosis. However, the effects of such introductions on the indigenous microbiota have not yet been investigated. Here, through a daily application of Lactobacillus reuteri DSM 17938 on volunteers’ forearm skin, we studied in vivo the impact of a probiotic on the indigenous skin bacterial community diversity using Terminal-Restriction Fragment Length Polymorphism (T-RFLP) for 3 weeks. The results demonstrate that Lactobacillus reuteri DSM 17938 inoculum had a transient effect on the indigenous community, as the resilience phenomenon was observed within the skin microbiota. Moreover, Lactobacillus reuteri DSM 17938 monitoring showed that, despite a high level of detection after 2 weeks of application, thereafter the colonization rate drops drastically. The probiotic colonization rate was correlated significantly to the effect on the indigenous microbial community structure. These preliminary results suggest that the success of probiotic use and the potential health benefits resides in the interactions with the human microbiota.
11
Ichsan, Burhannudin, Nining Lestari, and Sulistyani. "Lactobacillus Reuteri DSM 17938 in Infantile Colic: A Systematic Review and Meta-Analysis." Bioscientia Medicina : Journal of Biomedicine and Translational Research 6, no. 3 (2022): 1446–54. http://dx.doi.org/10.37275/bsm.v6i3.457.
Full textAbstract:
Background. Infantile colic, defined as paroxysmal, excessive, and consolable crying without an identifiable cause. It is common in the first 3 months of life. There have been many RCT studies conducted. A systematic synthesis is required to summarize the results of these RCTs. This study was aimed to systematically analyze the benefits of Lactobacillus reuteri DSM 17938 for infantile colic.
 Methods. This systematic review and meta-analysis used keywords: (“infantile colic” OR “abdominal cramps” OR “abdominal cramp” OR “infant colic”) AND “lactobacillus reuteri” AND (placebo OR placebos) AND (“randomized controlled trial” OR RCT). The databases used were: pubmed, science direct, and google scholar. Meta-analysis was conducted to combine the articles. The eligibility criteria were: patient with infantile colic, intervention with L. reuteri DSM 17938, control was placebo, RCT study design, outcome with dichotomous scale, all races, all ethnicities, all countries, all genders, in English, and not limited by year.
 Results. The search resulted in 800 articles. After reducing duplication, the number of articles was 747. Screening with titles and abstracts resulted in 13 full teks articles. Six articles fitted the eligibility criteria. The results of the meta-analysis were as follows. The forest plot showed that the combined effect of the six articles showed an RR of 0.47 and was statistically significant (p <0.001).
 Conclusion. Based on the results of this meta-analysis, L. reuteri DSM 17938 is recommended for infants with infantile colic. There were no significant side effects with the use of L. reuteri DSM 17938 on infantile colic.
12
Mamenko, M. E., and M. R. Romanko. "Effects of Lactobacillus reuteri DSM 17938 and vitamin D combination on the level of 25(OH)D in blood serum of young children." Modern pediatrics. Ukraine, no. 5(109) (September 28, 2020): 59–68. http://dx.doi.org/10.15574/sp.2020.109.59.
Full textAbstract:
Background. The search for optimal vitamin D levels and supplementation approaches to provide a wide range of preventive effects on the human body remains the focus of the world’s specialists. One of the promising directions is to improve the absorption of vitamin D in the gastrointestinal tract by using probiotics. Objective: to study the effect of using a combination of Lactobacillus reuteri DSM 17938 with vitamin D on the serum level of 25(OH)D in young children. Materials and methods. A total of 56 children from 1 to 36 months of age with the signs of functional gastrointestinal disorders were examined; 45 of them were randomized to participate in the comparative efficacy study of using a combination of 400 IU of cholecalciferol and 108 CFU of viable Lactobacillus reuteri DSM 17938 bacteria and an oily vitamin D solution at a dose of 500 IU for 12 weeks. At the start and the end of the study, the indicators of calcium and phosphorus metabolism (25(OH)D, total and ionized calcium, inorganic phosphorus, alkaline phosphatase) and the serum levels of total IgE were determined in all children, and the dynamics of the functional status of the gastrointestinal tract was assessed. Results. At baseline, the median serum concentration of 25(OH)D in children was 30.3 ng/mL (23.2–41.2); this indicator exceeded 30 ng/mL only in 53.3±7.4% (24/45) of cases. The use of a combination of vitamin D3 with Lactobacillus reuteri DSM 17938 made it possible to reach a statistical difference in the median concentration of 25(OH)D after 12 weeks of use compared to the same indicator at baseline: 37.4 ng/mL (30.2–52.3) versus 28.3 ng/mL (20.8–42.9), p=0.000. The level of 25(OH)D in all these children exceeded 20 ng/mL; the concentration level of 25(OH)D exceeded 30 ng/mL in 75.0±8.8% (18/24) of these. The use of 400 IU of vitamin D supplements in combination with L. reuteri for 12 weeks made it possible to reduce the median concentration of total IgE by almost half — from 64.1 IU/mL (9.2–120.0) to 31.9 IU/mL (6.4–143.6) but with significant individual variability of data. The use of vitamin D supplements in combination with Lactobacillus reuteri DSM 17938 had a positive effect on the functional activity of the gastrointestinal tract in young children and significantly reduced the frequency of parents’ complaints of stool retention and anxiety during defecation in their children. Conclusions. The use of vitamin D3 supplements at a dose of 400 IU in combination with the probiotic strain Lactobacillus reuteri DSM 17938 has a positive effect on the functional status of the gastrointestinal tract in young children and increases the serum level of 25(OH)D. The effects of vitamin D in combination with L. reuteri in children with a burdened history of allergies require further study. Key words: vitamin D; Lactobacillus reuteri DSM 17938; young children; supplementation.
13
Spreckels, Johanne E., Erik Wejryd, Giovanna Marchini, et al. "Lactobacillus reuteri Colonisation of Extremely Preterm Infants in a Randomised Placebo-Controlled Trial." Microorganisms 9, no. 5 (2021): 915. http://dx.doi.org/10.3390/microorganisms9050915.
Full textAbstract:
Lactobacillus reuteri DSM 17938 supplementation reduces morbidities in very low birth weight infants (<1500 g), while the effect on extremely low birth weight infants (ELBW, <1000 g) is still questioned. In a randomised placebo-controlled trial (ClinicalTrials.gov ID NCT01603368), head growth, but not feeding tolerance or morbidities, improved in L. reuteri-supplemented preterm ELBW infants. Here, we investigate colonisation with the probiotic strain in preterm ELBW infants who received L. reuteri DSM 17938 or a placebo from birth to postmenstrual week (PMW) 36. Quantitative PCR was used on 582 faecal DNA samples collected from 132 ELBW infants at one, two, three, and four weeks, at PMW 36, and at two years of age. Human milk oligosaccharides were measured in 31 milk samples at two weeks postpartum. At least 86% of the ELBW infants in the L. reuteri group were colonised with the probiotic strain during the neonatal period, despite low gestational age, high antibiotic pressure, and independent of infant feeding mode. Higher concentrations of lacto-N-tetraose, sialyl-lacto-N-neotetraose c, and 6′-sialyllactose in mother’s milk weakly correlated with lower L. reuteri abundance. Within the L. reuteri group, higher L. reuteri abundance weakly correlated with a shorter time to reach full enteral feeding. Female sex and L. reuteri colonisation improved head growth from birth to four weeks of age. In conclusion, L. reuteri DSM 17938 supplementation leads to successful colonisation in ELBW infants.
14
Kesavelu, Dhanasekhar. "The multifaceted use of Lactobacillus reuteri DSM 17938 in a pediatric clinic: a retrospective observational study." International Journal of Basic & Clinical Pharmacology 10, no. 9 (2021): 1134. http://dx.doi.org/10.18203/2319-2003.ijbcp20213370.
Full textAbstract:
Background: Lactobacillus reuteri DSM 17938 is a well-studied probiotic which colonizes many mammals. In humans, L. reuteri is found in various body sites including the gastrointestinal tract, urinary tract, skin and breast milk. It fulfills all the prerequisites of being a good probiotic as described by the world gastroenterology organization.Methods: This was a retrospective observational study, where a nutritional supplement L. reuteri DSM 17938 was given to 197 children, aged 0-16 years, along with normal diet. The participants were having complains of diarrhea, stomach pain and frequent hospitalization. Various parameters were recorded such as sex, age, anthropometry-weight and height (every visit), diagnosis, reason for outpatient visits and various demography including but not limited to- birthplace, current location, year in school, reason for hospital admission (if any). Paired t test was used to find difference in weight and height between each visit.Results: A total of 118 subjects were included in the analysis. Five drops of nutritional supplement L. reuteri DSM 17938 was given. Supplementation of L. reuteri reduced the need for hospital admissions. 96% children did not require hospital admission. It improved the overall health of the children. There was a statistical significance in the height and weight between first and second visits (p<0.001). A 7.65% weight increase was noted in between first and second visit. A 2.32% height increase was seen between first and second visit.Conclusions: L. reuteri DSM 17938 given as a nutritional supplement improved the health of the children and reduced the need for hospital admissions.
15
Szajewska, H., M. Urbańska, A. Chmielewska, Z. Weizman, and R. Shamir. "Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children." Beneficial Microbes 5, no. 3 (2014): 285–93. http://dx.doi.org/10.3920/bm2013.0056.
Full textAbstract:
Lactobacillus reuteri ATCC 55730 has been shown to provide a moderate clinical effect in the treatment of acute gastroenteritis (AGE) in children. However, as the L. reuteri ATCC 55730 strain was found to carry potentially transferable resistance traits for tetracycline and lincomycin, it was replaced by a new strain, L. reuteri DSM 17938, without unwanted plasmid-borne antibiotic resistance. Bioequivalence of the two strains has been suggested. We aimed to systematically evaluate data on the effectiveness of L. reuteri DSM 17938 and the original strain, L. reuteri ATCC 55730, in the treatment of AGE in children. The Cochrane Library, MEDLINE, and EMBASE databases, reference lists, and abstract books of major scientific meetings were searched in August 2013, with no language restrictions, for relevant randomised controlled trials (RCTs). Two RCTs (n=196) that evaluated L. reuteri DSM 17938 and three RCTs (n=156) that evaluated L. reuteri ATCC 55730, which involved hospitalised children aged 3 to 60 months, met the inclusion criteria. Compared with placebo or no treatment, DSM 17938 significantly reduced the duration of diarrhoea (mean difference -32 h, 95% confidence interval (CI): -41 to -24) and increased the chance of cure on day 3 (relative risk: 3.5, 95% CI: 1.2 to 10.8, random effects model). Similar results were obtained with the original strain, L. reuteri ATCC 55730. In conclusion, in hospitalised children, use of both strains of L. reuteri reduced the duration of diarrhoea, and more children were cured within 3 days. Data from outpatients and countryspecific cost-effectiveness analyses are needed. Given the limited data and the methodological limitations of the included trials, the evidence should be viewed with caution.
16
Olgac, Asburce, Oya Balcı Sezer, Ferda Ozbay Hosnut, and Figen Ozcay. "Lactobacillus reuteri DSM 17938 and quality of life associated with functional constipation." Slovenian Medical Journal 89, no. 7-8 (2020): 347–56. http://dx.doi.org/10.6016/zdravvestn.3024.
Full textAbstract:
Background: Functional constipation (FC) defines the form of constipation without an organic aetiology and influences the quality of life of the child in many aspects. In the present study, we aimed to compare the effects of Lactobacillus reuteri (L. reuteri) DSM 17938 and lactulose treatments on the health-related quality of life (HR-QoL) of constipated children and their families.Methods: Children with FC were divided into two groups to receive either L. Reuteri DSM 17938 (n = 25) or lactulose (n = 24), for four weeks. All patients and their parents completed the KINDL® HR-QoL questionnaire before and at the end of the treatment period.Results: The final total and disease perception scores and the subscale analyses of the probiotic and lactulose groups were comparable. The final mean total scores of parent questionnaires increased in both groups (68 % to 71.3 % in the probiotic group, 66.1 % to 70.9 % in the lactulose group), and the increase in the lactulose group was found statistically significant.Conclusion: In our study, L. reuteri DSM 17938 has showed to have comparable effects on the HR-QoL in children with FC, when compared to lactulose. Lactulose was more efficient regarding satisfaction of families and the family perception of HR-QoL.
17
Savitri, Tisa Rahmawaty, Sjarif Hidajat, and Anggraini Alam. "Pengaruh Lactobacillus reuteri DSM 17938 Terhadap Kadar Calprotectin Feses sebagai Penanda Inflamasi Intestinal pada Bayi Kurang Bulan." Sari Pediatri 20, no. 3 (2018): 171. http://dx.doi.org/10.14238/sp20.3.2018.171-7.
Full textAbstract:
Latar belakang. Bayi kurang bulan (BKB) berisiko mengalami inflamasi intestinal akibat imaturitas fungsi saluran cerna. Penelitian terdahulu melaporkan pro-kontra probiotik yang dapat menurunkan kejadian penyakit inflamasi intestinal pada BKB, seperti enterokolitis nekrotikans dan sepsis. Pengukuran calprotectin feses sebagai penanda penyakit inflamasi merupakan metode noninvasif, cepat, dan mudah dilakukan.Tujuan. Mengetahui pengaruh Lactobacillus reuteri DSM 17938 terhadap kadar calprotectin feses pada BKB. Metode. Penelitian eksperimental acak terkontrol pada BKB yang lahir di Rumah Sakit Dr. Hasan Sadikin Bandung selama bulan Maret sampai Juni 2018. Kelompok probiotik diberikan Lactobacillus reuteri DSM 17938 selama 14 hari dan kelompok kontrol diberikan plasebo. Kadar calprotectin feses diperiksa sebelum dan sesudah perlakuan. Calprotectin diperiksakan menggunakan metode enzymed-linked immunosorbent assay (ELISA). Data dianalisis menggunakan uji Mann-Whitney dan Wilcoxon Signed Rank, tingkat kemaknaan hasil uji ditentukan berdasarkan nilai p<0,05.Hasil. Empat puluh bayi diikutsertakan, 4 di antaranya mengalami dropout. Tiga puluh enam bayi yang dianalisis terbagi menjadi kelompok probiotik (n=18) dan nonprobiotik (n=18). Karakteristik dasar tidak berbeda antara kedua kelompok. Sebelum perlakuan, kadar calprotectin feses kedua kelompok tidak berbeda secara signifikan (p=0,88). Kadar calprotectin feses kelompok probiotik lebih rendah secara signifikan dibandingkan dengan kelompok nonprobiotik setelah perlakuan (p<0,001).Kesimpulan. Pemberian Lactobacillus reuteri DSM 17938 dapat menurunkan kadar calprotectin feses.
18
García Contreras, Andrea, Edgar Vásquez Garibay, Carmen Sánchez Ramírez, Mary Fafutis Morris, and Vidal Delgado Rizo. "Lactobacillus reuteri DSM 17938 and Agave Inulin in Children with Cerebral Palsy and Chronic Constipation: A Double-Blind Randomized Placebo Controlled Clinical Trial." Nutrients 12, no. 10 (2020): 2971. http://dx.doi.org/10.3390/nu12102971.
Full textAbstract:
The main objective was to assess the efficacy of a probiotic (Lactobacillus reuteri DSM 17938), a prebiotic (agave inulin), and a synbiotic on the stool characteristics in children with cerebral palsy and chronic constipation. Thirty-seven children with cerebral palsy and chronic constipation were included. The probiotic group received 1 × 108 colony forming unit (cfu) of L. reuteri DSM 17938 plus placebo, the prebiotic group received 4 g of agave inulin plus placebo, the synbiotic group received L. reuteri DSM 17938 plus agave inulin, and the placebo group received two placebos for 28 days. The probiotic group showed a significant decrease in stool pH (p = 0.014). Stool consistency improved in the prebiotic group (p = 0.008). The probiotic, prebiotic, and synbiotic groups showed a significant improvement in the history of excessive stool retention, the presence of fecal mass in the rectum, and the history of painful defecation. L. reuteri concentration in feces was higher in the probiotic group than in the placebo group (p = 0.001) and showed an inverse correlation with stool pH in the probiotic group (r = −0.762, p = 0.028). This study showed that the use of L. reuteri DSM 17938 and/or agave inulin improved the stool characteristics such as the history of painful defecation and the presence of fecal mass in the rectum against placebo in children with cerebral palsy and chronic constipation.
19
Zakharova, I. N., I. V. Berezhnaya, A. Е. Kuchina, and O. V. Dedikova. "Probiotic Lactobacillus reuteri DSM 17938: what is known about it today?" Medical Council, no. 17 (November 24, 2019): 236–42. http://dx.doi.org/10.21518/2079-701x-2019-17-236-242.
Full textAbstract:
The review is devoted to the analysis of data on the effects of Lactobacillus reuteri DSM 17938, confirmed in clinical trials. Thanks to their antimicrobial activity, L. reuteri is able to inhibit colonization by pathogenic microorganisms and restore the composition of compensatory intestinal microbiota. Another study showed a positive protective effect of intestinal microbiota when administered L. reuteri simultaneously with antibiotics. In addition, L. reuteri supports the immune system of the human body. For example, some strains of L. reuteri may reduce the production of pro-inflammatory cytokines while stimulating the development and proliferation of regulatory T-lymphocytes. Adding L. reuteri to the diet may be attractive in terms of preventing the development of inflammatory bowel disease. The results of a recent meta-analysis confirmed the efficacy of L. reuteri in the treatment of infantile colic. Further research is aimed at finding evidence of the efficacy of L. reuteri use in children who are artificially fed, with infant colic and in children born by caesarean section.
20
Manoppo, Jeanette I. Ch, Audrey M. I. Wahani, and Ernestine Vivi Sadeli. "The Role of Lactobacillus Reuteri DSM 17938 Reducing Indirect Bilirubin Levels in Neonatal Hyperbilirubinemia." Migration Letters 20, no. 7 (2023): 1347–57. http://dx.doi.org/10.59670/ml.v20i7.5809.
Full textAbstract:
Neonatal jaundice is a yellowish discoloration of the skin, conjunctiva, and sclera due to increased serum or plasma bilirubin in the neonatal period. This condition can cause parents' anxiety and increase the need to go to the hospital. In general, phototherapy was one of the therapeutic options to reduce neonatal hyperbilirubinemia with subsequent side effects such as dehydration, retinal damage, and bronze-baby syndrome. There is a need for further therapeutic options to treat neonatal hyperbilirubinemia with minimal side effects, and Lactobacillus was one of many options that have been proposed. This double-blind, randomized clinical trial was conducted to determine the role of Lactobacillus reuteri DSM 17938 to treat neonatal hyperbilirubinemia in conjunction with phototherapy. In conclusion, administration of Lactobacillus reuteri DSM 17938 can reduce indirect bilirubin levels in neonatal hyperbilirubinemia faster compared to the group without intervention (p-value 0.000).
21
Mai, Tu T., Dat Q. Tran, Stefan Roos, J. Marc Rhoads, and Yuying Liu. "Human Breast Milk Promotes the Secretion of Potentially Beneficial Metabolites by Probiotic Lactobacillus reuteri DSM 17938." Nutrients 11, no. 7 (2019): 1548. http://dx.doi.org/10.3390/nu11071548.
Full textAbstract:
Human breast milk (HBM) may have beneficial effects on Lactobacillus reuteri DSM 17938 (LR 17938) -mediated immunomodulation. We aimed to determine the effects of HBM on proliferation of LR 17938 in vitro and its associated proteins and metabolites in culture, in order to provide mechanistic insights into the health benefits of LR 17938. LR 17938 was cultured anaerobically in MRS bacterial culture media, HBM (from 6 mothers), and 2 types of cow-milk formula. The colony-forming unit (CFU) was calculated to evaluate LR 17938 growth. Sixteen-hour-fermented supernatants were used for metabolomics, and bacterial lysates were used for proteomics analysis. We found that growth of LR 17938 was 10 times better in HBM than in formula. We detected 261/452 metabolites upregulated when LR 17938 cultured in HBM compared to in formula, mainly participating in the glyoxylate cycle (succinate), urea cycle (citrulline), methionine methylation (N-acetylcysteine), and polyamine synthesis (spermidine). The significantly up-regulated enzymes were also involved in the formation of acetyl-CoA in the glyoxylate cycle and the antioxidant N-acetylcysteine. In conclusion, HBM enhances the growth of LR 17938 compared to formula and promotes LR 17938-associated metabolites that relate to energy and antioxidant status, which may be linked to the physiological effects of L. reuteri.
22
Sufaru, Irina-Georgeta, Luminita Lazar, Dorina-Cerasella Sincar, et al. "Clinical Effects of Locally Delivered Lactobacillus reuteri as Adjunctive Therapy in Patients with Periodontitis: A Split-Mouth Study." Applied Sciences 12, no. 5 (2022): 2470. http://dx.doi.org/10.3390/app12052470.
Full textAbstract:
Different methods and products have been investigated as measures of adjunctive therapy to scaling and root planing (SRP). Probiotic use has gained interest for this particular application, especially Lactobacillus spp. This split-mouth interventional prospective study aimed to evaluate the clinical effects of L. reuteri DSM 17938 with local application in periodontal pockets of severe periodontitis patients. The study was conducted on 40 subjects with stage 3–4 periodontitis who, based on a split-mouth model, followed SRP and SRP + L. reuteri solution in five weekly sessions. Probing depth (PD), clinical attachment loss (CAL), and bleeding on probing (BOP) were assessed at baseline and at three months after probiotic treatment completion. Both SRP and SRP + L. reuteri generated significant improvements of all three clinical parameters, but the changes were significantly better for SRP + L. reuteri treated sites. Therefore, we can conclude that adjunctive therapy with L. reuteri DSM 17938 could represent an interesting treatment option, particularly for severe periodontitis cases.
23
Maragkoudaki, Maria, George Chouliaras, Antonia Moutafi, Athanasios Thomas, Archodoula Orfanakou, and Alexandra Papadopoulou. "Efficacy of an Oral Rehydration Solution Enriched with Lactobacillus reuteri DSM 17938 and Zinc in the Management of Acute Diarrhoea in Infants: A Randomized, Double-Blind, Placebo-Controlled Trial." Nutrients 10, no. 9 (2018): 1189. http://dx.doi.org/10.3390/nu10091189.
Full textAbstract:
The efficacy of oral rehydration solution (ORS) enriched with Lactobacillus reuteri DSM 17938 and zinc in infants with acute gastroenteritis, is poorly defined. The aim of this double-blind, randomized, placebo-controlled study, was to assess the efficacy of an ORS enriched with Lactobacillus reuteri DSM 17938 and zinc (ORS+Lr&Z) in well-nourished, non-hospitalized infants with acute diarrhoea. Fifty one infants with acute diarrhoea were randomly assigned to receive either ORS+Lr&Z (28 infants, mean ± SD age 1.7 ± 0.7 years, 21 males), or standard ORS (ORS−Lr&Z; 23 infants, mean ± SD age 1.8 ± 0.7 years, 16 males). Stools volume and consistency were recorded pre- and posttreatment using the Amsterdam Infant Stool Scale and were compared between the two groups, as well as lost work/day care days, drug administration and need for hospitalization. Both groups showed reduction in the severity of diarrhoea on day two (p < 0.001) while, all outcomes showed a trend to be better in the ORS+Lr&Z group, without reaching statistical significance, probably due to the relatively small number of patients. No adverse effects were recorded. In conclusion, both ORS were effective in managing acute diarrhoea in well-nourished, non-hospitalized infants. ORS enriched with L. reuteri DSM 17938 and zinc was well tolerated with no adverse effects.
24
Dommels, Yvonne E. M., Robèr A. Kemperman, Yvonne E. M. P. Zebregs, et al. "Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the Human Gastrointestinal Tract with Daily Consumption of a Low-Fat Probiotic Spread." Applied and Environmental Microbiology 75, no. 19 (2009): 6198–204. http://dx.doi.org/10.1128/aem.01054-09.
Full textAbstract:
ABSTRACT Probiotics are live microorganisms which, when administered in adequate amounts, confer a health benefit on the host. Therefore, probiotic strains should be able to survive passage through the human gastrointestinal tract. Human gastrointestinal tract survival of probiotics in a low-fat spread matrix has, however, never been tested. The objective of this randomized, double-blind, placebo-controlled human intervention study was to test the human gastrointestinal tract survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG after daily consumption of a low-fat probiotic spread by using traditional culturing, as well as molecular methods. Forty-two healthy human volunteers were randomly assigned to one of three treatment groups provided with 20 g of placebo spread (n = 13), 20 g of spread with a target dose of 1 × 109 CFU of L. reuteri DSM 17938 (n = 13), or 20 g of spread with a target dose of 5 × 109 CFU of L. rhamnosus GG (n = 16) daily for 3 weeks. Fecal samples were obtained before and after the intervention period. A significant increase, compared to the baseline, in the recovery of viable probiotic lactobacilli in fecal samples was demonstrated after 3 weeks of daily consumption of the spread containing either L. reuteri DSM 17938 or L. rhamnosus GG by selective enumeration. In the placebo group, no increase was detected. The results of selective enumeration were supported by quantitative PCR, detecting a significant increase in DNA resulting from the probiotics after intervention. Overall, our results indicate for the first time that low-fat spread is a suitable carrier for these probiotic strains.
25
Gutiérrez-Castrellón, Pedro, Flavia Indrio, Alexis Bolio-Galvis, Carlos Jiménez-Gutiérrez, Irma Jimenez-Escobar, and Gabriel López-Velázquez. "Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic." Medicine 96, no. 51 (2017): e9375. http://dx.doi.org/10.1097/md.0000000000009375.
Full text
26
Riezzo, G., A. Orlando, B. D’Attoma, M. Linsalata, M. Martulli, and F. Russo. "Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and bowel habit in functional constipation." Beneficial Microbes 9, no. 1 (2018): 51–60. http://dx.doi.org/10.3920/bm2017.0049.
Full textAbstract:
Dysbiosis may contribute to constipation and its symptoms, therefore probiotic administration could improve significantly gut health and functions. The aim of the study was to investigate the effects of a long-lasting administration of Lactobacillus reuteri DSM 17938 (LR DSM 17938) on symptoms and quality of life (QoL) score in patients with functional constipation (FC). 56 FC patients with normal colonic transit time and without anorectal disorders and pelvic floor dysfunctions completed the study. LR DSM 17938 was administered for 105 days in a randomised double-blind clinical trial (28 patients per arm). Individual and cumulative scores including the Constipaq, a modified Constipation Scoring System (CSS) that considers the patient assessment of constipation-QoL (PAC-QoL), were calculated during the preliminary visit (V0), at day 15 (end of the induction period with a LR DSM 17938 double dosage, 4×108 cfu), day 60 (intermediate evaluation) and day 105 (V4) after a standard dosage (2×108 cfu). At the end of treatment, the beneficial effect of LR DSM 17938 compared to placebo was significantly evident for symptoms related to gas content and dysbiosis (abdominal discomfort, pain and bloating), incomplete defecation and helps for defecation (P<0.05). At the end of the whole LR DSM 17938 treatment, a marked and positive effect on both the CSS single and the cumulative items was evident with the exception of unfruitful attempt and Bristol score. Present findings indicate that LR DSM 17938 has an effect on symptoms different from stool consistency, and they suggest that this probiotic can effectively be used in association therapy rather than as single-drug therapy in the management of FC.
27
Dobryk, D. S., and D. O. Dobryanskyy. "Probiotics, gut microbiota, and diseases associated with the immaturity of the digestive tract in very preterm infants." Modern pediatrics. Ukraine, no. 3(131) (April 28, 2023): 22–30. http://dx.doi.org/10.15574/sp.2023.131.22.
Full textAbstract:
Interruption of the formation of gut microbiota in preterm infants increases the probability of necrotizing enterocolitis (NEC) and late-onset neonatal sepsis (LOS). The use of probiotics can reduce the corresponding risk. Purpose - to evaluate the clinical effectiveness of enteral administration of Lactobacillus reuteri DSM 17938 in reducing the incidence of NEC, LOS, and overall mortality in infants with gestational age (GA) ≤32 weeks, as well as the effect of the probiotic on the formation of the gut microbiota. Materials and methods. 100 newborns with GA ≤32 weeks and birth weight ≤1500 g were enrolled in the open randomized study. 50 infants in the probiotic group until reaching postmenstrual age (PMA) of 36 weeks received Lactobacillus reuteri DSM 17938 at a dose of 108 CFU/day with enteral feeding (EF), and 50 infants in the comparison group received standard treatment. The primary effectiveness criteria were the incidence of NEC, LOS, and overall mortality. As the secondary criteria, the duration of the period to reach the full EF, the number of episodes of feeding intolerance, duration of antibacterial therapy, weight at PMA of 36 weeks, and length of hospital stay were used. Results. The administration of Lactobacillus reuteri DSM 17938 at a dose of 108 CFU/day neither reduced the incidence of NEC and LOS nor overall mortality. This intervention, however, significantly reduced the length of hospital stay in infants with GA ≥28 weeks (56.0 (46.0-71.0) days vs 65.0 (60.0-87.9) days; р=0.03), and was associated with the earlier achievement of full enteral volume (23.0 (16.0-37.0) days vs 30.0 (18.0-37.0) days; р=0.26) and fewer episodes of feeding intolerance in infants with GA <28 weeks (1.0 (1.0-3.0) vs 3.0 (3.0-4.0); р=0.19). No effect of the probiotic therapy on the gut colonization by Lactobacillus spp. and Bifidobacterium spp. was observed. Conclusions. Enteral administration of Lactobacillus reuteri DSM 17938 improves tolerance to EF and reduces the period to achieve full EF and the total length of hospital stay in preterm infants. The effect of this probiotic on the incidence of NEC and LOS, as well as the postnatal formation of the gut microbiota, requires further study. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of all participating institutions. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
28
Hoang, Thomas K., Baokun He, Ting Wang, Dat Q. Tran, J. Marc Rhoads, and Yuying Liu. "Protective effect of Lactobacillus reuteri DSM 17938 against experimental necrotizing enterocolitis is mediated by Toll-like receptor 2." American Journal of Physiology-Gastrointestinal and Liver Physiology 315, no. 2 (2018): G231—G240. http://dx.doi.org/10.1152/ajpgi.00084.2017.
Full textAbstract:
Lactobacillus reuteri DSM 17938 (LR 17938) has been shown to reduce the incidence and severity of necrotizing enterocolitis (NEC). It is unclear if preventing NEC by LR 17938 is mediated by Toll-like receptor 2 (TLR2), which is known to mediate proinflammatory responses to bacterial cell wall components. NEC was induced in newborn TLR2−/− or wild-type (WT) mice by the combination of gavage-feeding cow milk-based formula and exposure to hypoxia and cold stress. Treatment groups were administered formula supplemented with LR 17938 or placebo (deMan-Rogosa-Sharpe media). We observed that LR 17938 significantly reduced the incidence of NEC and reduced the percentage of activated effector CD4+T cells, while increasing Foxp3+ regulatory T cells in the intestinal mucosa of WT mice with NEC, but not in TLR2−/− mice. Dendritic cell (DC) activation by LR 17938 was mediated by TLR2. The percentage of tolerogenic DC in the intestine of WT mice was increased by LR 17938 treatment during NEC, a finding not observed in TLR2−/− mice. Furthermore, gut levels of proinflammatory cytokines IL-1β and IFN-γ were decreased after treatment with LR 17938 in WT mice but not in TLR2−/− mice. In conclusion, the combined in vivo and in vitro findings suggest that TLR2 receptors are involved in DC recognition and DC-priming of T cells to protect against NEC after oral administration of LR 17938. Our studies further clarify a major mechanism of probiotic LR 17938 action in preventing NEC by showing that neonatal immune modulation of LR 17938 is mediated by a mechanism requiring TLR2. NEW & NOTEWORTHY Lactobacillus reuteri DSM 17938 (LR 17938) has been shown to protect against necrotizing enterocolitis (NEC) in neonates and in neonatal animal models. The role of Toll-like receptor 2 (TLR2) as a sensor for gram-positive probiotics, activating downstream anti-inflammatory responses is unclear. Our current studies examined TLR2 −/− mice subjected to experimental NEC and demonstrated that the anti-inflammatory effects of LR 17938 are mediated via a mechanism requiring TLR2.
29
Kaban, Risma K., Wardhana, Badriul Hegar, et al. "Lactobacillus reuteri DSM 17938 Improves Feeding Intolerance in Preterm Infants." Pediatric Gastroenterology, Hepatology & Nutrition 22, no. 6 (2019): 545. http://dx.doi.org/10.5223/pghn.2019.22.6.545.
Full text
30
Athalye-Jape, Gayatri, Shripada Rao, and Sanjay Patole. "Lactobacillus reuteri DSM 17938 as a Probiotic for Preterm Neonates." Journal of Parenteral and Enteral Nutrition 40, no. 6 (2016): 783–94. http://dx.doi.org/10.1177/0148607115588113.
Full text
31
Ukraintsev, S. E., E. A. Kornienko, L. I. Kafarskaya, and M. I. Dubrovskaya. "MICROBES INSIDE OUR BODIES: CASUAL COMPANIONS, OR PREREQUISITE FOR OUR SURVIVAL? OR WHY PROBIOTICS ARE NEEDED IN INFANT FORMULAE." Pediatria. Journal named after G.N. Speransky 99, no. 6 (2020): 163–71. http://dx.doi.org/10.24110/0031-403x-2020-99-6-163-171.
Full textAbstract:
This literature review describes evolutionary aspects of the formation of relationships between microorganisms and the human body. The formation of symbiotic relationships, which resulted in the formation of a holobiont, is discussed. Separate chapter of the article is dedicated to describing positive effects of Lactobacillus reuteri DSM 17938 strain for human health, including effective prevention and treatment of functional gastrointestinal disorders in infants.
32
Borrell García, Carla, Marta Ribelles Llop, Maria Ángeles García Esparza, Antonio Juan Flichy-Fernández, Laura Marqués Martínez, and Regina Izquierdo Fort. "The use of Lactobacillus reuteri DSM 17938 and ATCC PTA 5289 on oral health indexes in a school population: A pilot randomized clinical trial." International Journal of Immunopathology and Pharmacology 35 (January 2021): 205873842110311. http://dx.doi.org/10.1177/20587384211031107.
Full textAbstract:
To assess the effects of a probiotic upon oral health indices in adolescents and to establish relationships between these indices and dietary habits and oral hygiene. Twenty-seven adolescents between 12 and 18 years of age were randomized into two groups. The study group received tablets containing Lactobacillus reuteri DSM 17938/ ATCC 5289 for 28 days, while the control group received tablets without any bacteria. Streptococcus mutans, Lactobacillus sp., and salivary pH were assessed at baseline and at 7, 14, 21, 28, and 45 days. The plaque, gingivitis, and bleeding indices were recorded at baseline and at 14, 28, and 45 days. Dietary and oral hygiene habits were also evaluated by means of a questionnaire. A less marked rise in S. mutans was recorded in the study group. Improvements were observed in terms of plaque, gingivitis, and bleeding, though statistical significance was not reached. Oral pH increased in the study group, though not to a significant degree. Poorer eating habits were significantly correlated to increased plaque. The study parameters decreased with the two strains of L. reuteri DSM 17938 and ATCC PTA 5289, though the results failed to reach statistical.
33
Dedikova, О. V., I. N. Zakharova, A. E. Kuchina, I. V. Berezhnaya, N. G. Sugian, and M. D. Ardatskaya. "Intestinal microbiota features of children born by cesarean section and its correction." Meditsinskiy sovet = Medical Council, no. 1 (February 26, 2024): 176–88. http://dx.doi.org/10.21518/ms2024-005.
Full textAbstract:
Introduction. Studying the gut microbiota of C-section newborns and its correction is a topical problem at present.Aim. To study the process of gut microbiota formation in healthy C-section infants, and the option for its correction using a Lactobacillus reuteri strain DSM 17938 probiotic.Materials and methods. A total of 80 healthy newborns were included in the study. Of these, 59 completed the study: the treatment group consisted of 36 elective caesarean (EC)-section infants and the control group was made up of 23 vaginally delivered infants. Newborns of the treatment study group were randomized into subgroups, one of which received the L. reuteri strain DSM 17938 (L subgroup) probiotic, and the second one did not receive it (0 subgroup). During the entire period of the study, infants were exclusively breastfed. The gut microbiota was analysed with the 16S rRNA sequencing method, and the metabolic activity of the gut microbiota was additionally assessed using gas-liquid chromatography.Results and discussion. The metagenomic analysis showed that the taxonomic richness and biological diversity of the gut microbiota in L subgroup infants increased in time interval 3, which indicated the active effect of the strain on the infant microbiota by Exposure Day 30. The gas-liquid chromatography analysis showed more pronounced changes in short-chain fatty acids in infants of the L subgroup: they were more similar to the findings in the control group (vaginal delivery). Also, bowel problems and allergies occurred less frequently in infants of this subgroup and they less frequently suffered from respiratory diseases during the year. The study showed the association between the mode of delivery and changes in anthropometric measurements.Conclusion. The use of L. reuteri strain DSM 17938 probiotic had a significant effect on the formation of the microbiota by the 30th day of age. A daily long-term addition of a L. reuteri strain DSM 17938 probiotic can prevent early microbiota dysbiosis and have a protective effect in later age period.
34
Novikova, V. P., and A. I. Khavkin. "Zinc deficiency and intestinal microbiota." Voprosy praktičeskoj pediatrii 16, no. 3 (2021): 92–98. http://dx.doi.org/10.20953/1817-7646-2021-3-92-98.
Full textAbstract:
Zinc is one of the most important trace elements in the human metabolism. This micronutrient is an important component of more than 300 enzymes that regulate anabolism and catabolism of carbohydrates, proteins, fats, and nucleic acids, as well as the expression of several genes. Zinc is essential for the formation and functioning of the immune system; it supports normal growth and development of the fetus during pregnancy, development during childhood and adolescence, and is necessary for normal sense of smell and taste. There is a confirmed association between zinc and gastrointestinal (GI) disorders: on the one hand, GI diseases with malabsorption syndrome cause zinc deficiency; on the other hand, zinc deficiency affects normal functioning of the GI mucosa, which manifests as different forms of chronic diarrhea, celiac disease, and Crohn's disease. There is a therapeutic strategy for the treatment of chronic diarrhea, which implies administration of a multicomponent medication containing the probiotic L. reuteri Protectis (L. reuteri DSM 17938), zinc, and a solution for oral rehydration. It ensures fluid and electrolyte replenishment, while zinc enhances their absorption, and probiotics increase natural protection of the digestive tract. Key words: Lactobacillus reuteri DSM 17938, zinc, zinc deficiency, chronic diarrhea, rehydration, children
35
Liu, Yuying, Nicole Y. Fatheree, Nisha Mangalat та Jon Marc Rhoads. "Lactobacillus reuteristrains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestine". American Journal of Physiology-Gastrointestinal and Liver Physiology 302, № 6 (2012): G608—G617. http://dx.doi.org/10.1152/ajpgi.00266.2011.
Full textAbstract:
Necrotizing enterocolitis (NEC) is the leading gastrointestinal cause of mortality and morbidity in the premature infant. Premature infants have a delay in intestinal colonization by commensal bacteria and colonization with potentially pathogenic organisms. Lactobacillus reuteri is a probiotic that inhibits enteric infections, modulates the immune system, and may be beneficial to prevent NEC. In previous studies, L. reuteri strains DSM 17938 and ATCC PTA 4659 differentially modulated inflammation in vitro; however, the strains had equivalent anti-inflammatory responses in LPS feeding-induced ileitis in neonatal rats in vivo. The impact of these two strains in the prevention of NEC has not been previously investigated. NEC was induced in newborn rats by orogastric formula feeding and exposure to hypoxia. L. reuteri was added to the formula to prevent NEC. NEC score, Toll-like receptor (TLR)-signaling genes, phospho-IκB activity, and cytokine levels in the intestine were examined. Both strains significantly increased survival rate and decreased the incidence and severity of NEC, with optimal effects from DSM 17938. In response to probiotic, mRNA expression of IL-6, TNF-α, TLR4, and NF-κB was significantly downregulated, while mRNA levels of anti-inflammatory cytokine IL-10 were significantly upregulated. In parallel, L. reuteri treatment led to decrease intestinal protein levels of TLR4 and cytokine levels of TNF-α and IL-1β in newborn rats with NEC. Both strains significantly inhibited not only intestinal LPS-induced phospho-IκB activity in an ex vivo study but also decreased the levels of phospho-IκB in the intestines of NEC rat model. Cow milk formula feeding produced a similar but milder proinflammatory profile in the intestine that was also ameliorated by 17938. Our studies demonstrate that each of the two L. reuteri strains has potential therapeutic value in our NEC model and in enteritis associated with cow milk feeding. These results support the concept that L. reuteri may represent a valuable treatment to prevent NEC.
36
Liu, Yuying, Nicole Y. Fatheree, Nisha Mangalat, and Jon Marc Rhoads. "Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation." American Journal of Physiology-Gastrointestinal and Liver Physiology 299, no. 5 (2010): G1087—G1096. http://dx.doi.org/10.1152/ajpgi.00124.2010.
Full textAbstract:
Lactobacillus reuteri ( L. reuteri ) is a probiotic that inhibits the severity of enteric infections and modulates the immune system. Human-derived L. reuteri strains DSM17938, ATCC PTA4659, ATCC PTA 5289, and ATCC PTA 6475 have demonstrated strain-specific immunomodulation in cultured monocytoid cells, but information about how these strains affect inflammation in intestinal epithelium is limited. We determined the effects of the four different L. reuteri strains on lipopolysaccharide (LPS)-induced inflammation in small intestinal epithelial cells and in the ileum of newborn rats. IPEC-J2 cells (derived from the jejunal epithelium of a neonatal piglet) and IEC-6 cells (derived from the rat crypt) were treated with L. reuteri . Newborn rat pups were gavaged cow milk formula supplemented with L. reuteri strains in the presence or absence of LPS. Protein and mRNA levels of cytokines and histological changes were measured. We demonstrate that even though one L. reuteri strain (DSM 17938) did not inhibit LPS-induced IL-8 production in cultured intestinal cells, all strains significantly reduced intestinal mucosal levels of KC/GRO (∼IL-8) and IFN-γ when newborn rat pups were fed formula containing LPS ± L. reuteri . Intestinal histological damage produced by LPS plus cow milk formula was also significantly reduced by all four strains. Cow milk formula feeding (without LPS) produced mild gut inflammation, evidenced by elevated mucosal IFN-γ and IL-13 levels, a process that could be suppressed by strain 17938. Other cytokines and chemokines were variably affected by the different strains, and there was no toxic effect of L. reuteri on intestinal cells or mucosa. In conclusion, L. reuteri strains differentially modulate LPS-induced inflammation. Probiotic interactions with both epithelial and nonepithelial cells in vivo must be instrumental in modulating intrinsic anti-inflammatory effects in the intestine. We suggest that the terms anti- and proinflammatory be used only to describe the effects of a probiotic in the living host.
37
Saviano, Angela, Mattia Brigida, Alessio Migneco, et al. "Lactobacillus Reuteri DSM 17938 (Limosilactobacillus reuteri) in Diarrhea and Constipation: Two Sides of the Same Coin?" Medicina 57, no. 7 (2021): 643. http://dx.doi.org/10.3390/medicina57070643.
Full textAbstract:
Background and Objectives: Lactobacillus reuteri DSM 17938 (L. reuteri) is a probiotic that can colonize different human body sites, including primarily the gastrointestinal tract, but also the urinary tract, the skin, and breast milk. Literature data showed that the administration of L. reuteri can be beneficial to human health. The aim of this review was to summarize current knowledge on the role of L. reuteri in the management of gastrointestinal symptoms, abdominal pain, diarrhea and constipation, both in adults and children, which are frequent reasons for admission to the emergency department (ED), in order to promote the best selection of probiotic type in the treatment of these uncomfortable and common symptoms. Materials and Methods: We searched articles on PubMed® from January 2011 to January 2021. Results: Numerous clinical studies suggested that L. reuteri may be helpful in modulating gut microbiota, eliminating infections, and attenuating the gastrointestinal symptoms of enteric colitis, antibiotic-associated diarrhea (also related to the treatment of Helicobacter pylori (HP) infection), irritable bowel syndrome, inflammatory bowel disease, and chronic constipation. In both children and in adults, L. reuteri shortens the duration of acute infectious diarrhea and improves abdominal pain in patients with colitis or inflammatory bowel disease. It can ameliorate dyspepsia and symptoms of gastritis in patients with HP infection. Moreover, it improves gut motility and chronic constipation. Conclusion: Currently, probiotics are widely used to prevent and treat numerous gastrointestinal disorders. In our opinion, L. reuteri meets all the requirements to be considered a safe, well-tolerated, and efficacious probiotic that is able to contribute to the beneficial effects on gut-human health, preventing and treating many gastrointestinal symptoms, and speeding up the recovery and discharge of patients accessing the emergency department.
38
Patro-Gołąb, Bernadeta, and Hania Szajewska. "Systematic Review with Meta-Analysis: Lactobacillus reuteri DSM 17938 for Treating Acute Gastroenteritis in Children. An Update." Nutrients 11, no. 11 (2019): 2762. http://dx.doi.org/10.3390/nu11112762.
Full textAbstract:
The effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri) for the management of acute gastroenteritis (AGE) has been recently questioned. We performed a systematic review to update evidence on L. reuteri for treating AGE in children. We searched MEDLINE, EMBASE, the Cochrane Library databases, and additional data sources from January 2016 (end of search for our 2016 systematic review) to August 2019. The primary outcomes were stool volume and duration of diarrhea. Four RCTs were included. None of them evaluated stool volume. Compared with placebo or no treatment, L. reuteri reduced diarrhea duration (four RCTs, n = 347, mean difference, MD −0.87 days, 95% CI [−1.43, −0.31]). L. reuteri use was also associated with a reduced duration of hospitalization (three RCTs, n = 284, MD −0.54 days, 95% CI [−1.09, 0.0]). The small effect sizes of limited clinical relevance and methodological limitations of the included trials should be noted when interpreting these findings.
39
Barboza, Yasmina, Nibia Novillo, and Dolores Zambrano. "Efecto de diferentes formulaciones preparadas con cereales y leguminosas sobre el crecimiento de Lactobacillus reuteri DSM 17938." Revista Científica de la Facultad de Ciencias Veterinarias XXXIV, no. 1 (2024): 1–7. http://dx.doi.org/10.52973/rcfcv-e34297.
Full textAbstract:
Los efectos beneficiosos de los microorganismos probióticos cuando se ingieren en cantidad suficiente tienen una influencia positiva para la salud de los seres humanos y animales. Los probióticos, especialmente los Lactobacilos, pueden inhibir el crecimiento de patógenos y mejorar la inmunología y las funciones metabólicas del hospedador. Las cepas de Lactobacillus reuteri son habitantes comunes del intestino de los mamíferos y exhiben propiedades que promueven la salud. Por esta razón, el objetivo de este trabajo fue determinar el efecto de diferentes formulaciones preparadas con cereales y leguminosas sobre el crecimiento de L. reuteri DSM 17938. Para esto, en el presente trabajo, sustratos solos o mezclas de cereales y leguminosas fueron fermentados con L. reuteri DSM 17938 para estudiar y comparar el efecto de la formulación de los medios sobre su crecimiento. Los medios se formularon utilizando dos harinas de cereales y dos de leguminosas: cebada, avena, quinchoncho y soja y mezclas de cereales y leguminosas (soja– avena, cebada–soja, quinchoncho–avena y quinchoncho–cebada). Se prepararon dos tratamientos un medio sólido (T1) y otro medio líquido (T2). Los resultados mostraron que hubo diferencias significativas (P<0,05) en el crecimiento de L. reuteri entre los medios de cereales y leguminosas y sus mezclas. No hubo diferencias significativas (P>0,05) entre los medios sólidos y líquido. El medio de cebada (8,87 log UFC·g-1) soportó significativamente mejor crecimiento en comparación con los medios de avena, soja y quinchoncho. La población de células de L. reuteri en los medios con mezclas de cereales y leguminosas varió de 9,01 a 7,32 log UFC·g-1. La combinación de soja y avena fue la más eficiente en mantener la viabilidad. Los valores de pH estuvieron entre 4 y 5.
40
Jiang, Huiyong, Ren Yan, Kaicen Wang, et al. "Lactobacillus reuteri DSM 17938 alleviates d-galactosamine-induced liver failure in rats." Biomedicine & Pharmacotherapy 133 (January 2021): 111000. http://dx.doi.org/10.1016/j.biopha.2020.111000.
Full text
41
Knysh, O.V., A.V. Martynov, Yu.V. Voyda, and Ye.M. Babych. "The influence of polyols on the bacteriotropic properties of the Lactobacillus reuteri cell-free superants." Annals of Mechnikov Institute, no. 1 (March 25, 2020): 27–31. https://doi.org/10.5281/zenodo.3726635.
Full textAbstract:
<strong>Introduction</strong><strong>. </strong>Precursor directed biosynthesis is one of the promising approaches to finding new antimicrobial agents and creating next-generation probiotics. <em>L. reuteri</em> is capable to convert triatomic polyol glycerol into reuterine, a broad-spectrum antimicrobial substance. There are no data on the use of other polyols as precursors. The aim of the research was to investigate the effect of cell-free supernatants obtained by culturing <em>L. reuteri</em> DSM 17938 in its own disintegrate, supplemented with polyols (xylitol, sorbitol, mannitol and glycerol & glucose) on the daily biomass growth of opportunistic microorganisms. <strong>Material</strong><strong> & </strong><strong>methods. </strong>Reference strains <em>Staphylococcus</em> <em>aureus</em> ATCC 25923; <em>Escherichia</em> <em>coli</em> AТСС 25922 and <em>Pseudomonas aeruginosa</em> clinical isolate were used as a test cultures. The effect of the lactobacillus supernatant on the daily biomass growth of the test cultures was investigated by spectrophotometry using a 96-well polystyrene microtiter plates and a «LisaScanEM» spectrophotometer («ErbaLachemas.r.o.», Czech Republic). The final concentration of supernatants in the incubation medium was 30%, and the final concentration of bacterial cells was ~10<sup>6</sup> CFU/ml. Inhibition (II) or stimulation (SI) indices of the daily biomass growth of test cultures by formula were calculated. <strong>Results & discussion</strong><strong>. </strong>Supplementation of culture medium with glycerol & glucose during <em>L. reuteri</em> cultivation resulted in the <em>S. aureus</em> (II = 70.7%), <em>Escherichia coli</em> (II = 72.2%) and P. aeruginosa (II = 74.7%) daily biomass growth inhibition. As a result of <em>L. reuteri</em> cultivation in its own disintegrate supplemented with mannitol, the supernatant acquired growth-promoting properties with respect to <em>S. aureus</em> (SI = 45.5%), <em>E. coli</em> (SI = 19.1%) and <em>P. aeruginosa</em> (SI = 19, 9%). The supernatant obtained after <em>L. reuteri </em>cultivation in disintegrate supplemented with sorbitol had no significant effect on the <em>S. aureus</em> and <em>Escherichia coli</em> daily biomass growth, but significantly stimulated the growth of <em>P. aeruginosa</em> (SI = 29.4%). The supernatant of <em>L. reuteri</em>, cultured in disintegrate supplemented with xylitol had no effect on staphylococcus growth, inhibited of <em>E. coli</em> (II = 16.5%) growth and increased of <em>P. aeruginosa</em> (SI = 19.1%) daily biomass growth. The data obtained for glycerol, the introduction of which into the culture medium of <em>L. reuteri </em>led to the appearance of inhibitory activity of the supernatant against all test cultures, were expected. They coincide with the results of studies by other authors and are associated with the ability of this type of lactobacilli to convert glycerol into a broad-spectrum antimicrobial substance reuterin. The results of the study confirm that xylitol, sorbitol and mannitol do not undergo fermentation with the formation of acidic end products during the cultivation of <em>L. reuteri</em>. These polyols remain either unchanged or undergo slight modification in the composition of the supernatant and have different effects on the daily biomass growth of test cultures. <strong>Conclusion</strong><strong>. </strong>The results of the study showed that the use of xylitol, sorbitol and mannitol as precursors, and <em>L. reuteri</em> DSM 17938 as a biotransformer system in the development of new antimicrobials using a precursor-directed biosynthesis strategy is ineffective. They also confirmed that the supernatant obtained after cultivation of <em>L</em><em>. reuteri</em> DSM 17938 in its own disintegrate supplemented with glycerol & glucose, has a pronounced inhibitory activity against the investigated opportunistic microorganisms.
42
Piatek, Jacek, Hanna Krauss, Arleta Ciechelska-Rybarczyk, Malgorzata Bernatek, Paulina Wojtyla-Buciora, and Henning Sommermeyer. "In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters." International Journal of Environmental Research and Public Health 17, no. 9 (2020): 3332. http://dx.doi.org/10.3390/ijerph17093332.
Full textAbstract:
A variety of activities potentially contribute to the beneficial effects of probiotic bacteria observed in humans. Among these is a direct inhibition of the growth of pathogenic bacteria in the gut. The present study characterizes head-to-head the in-vitro pathogen growth inhibition of clinically relevant infectious bacterial strains by different types of probiotics and a synbiotic. In-vitro growth inhibition of Escherichia (E.) coli EPEC, Shigella (Sh.) sonnei, Salmonella (S.) typhimurium, Klebsiella (K.) pneumoniae and Clostridioides (C.) difficile were determined. Investigated products were a yeast mono strain probiotic containing Saccharomyces (Sac.) boulardii, bacterial mono strain probiotics containing either Lactobacillus (L.) rhamnosus GG or L. reuteri DSM 17938, a multi strain probiotic containing three L. rhamnosus strains (E/N, Oxy, Pen), and a multi strain synbiotic containing nine different probiotic bacterial strains and the prebiotic fructooligosaccharides (FOS). Inhibition of pathogens was moderate by Sac. boulardii and L. rhamnosus GG, medium by L. reuteri DSM 17938 and the L. rhamnosus E/N, Oxy, Pen mixture and strong by the multi strain synbiotic. Head-to-head in-vitro pathogen growth inhibition experiments can be used to differentiate products from different categories containing probiotic microorganisms and can support the selection process of products for further clinical evaluation.
43
Pernica, Jeffrey M., Tonya Arscott-Mills, Andrew P. Steenhoff, et al. "Optimising the management of childhood acute diarrhoeal disease using a rapid test-and- treat strategy and/or Lactobacillus reuteri DSM 17938: a multicentre, randomised, controlled, factorial trial in Botswana." BMJ Global Health 7, no. 4 (2022): e007826. http://dx.doi.org/10.1136/bmjgh-2021-007826.
Full textAbstract:
IntroductionThe study aim was to determine if rapid enteric diagnostics followed by the provision of targeted antibiotic therapy (‘test-and-treat’) and/or Lactobacillus reuteri DSM 17938 would improve outcomes in children hospitalised in Botswana with acute gastroenteritis.MethodsThis was a multicentre, randomised, factorial, controlled, trial. Children aged 2–60 months admitted for acute non-bloody diarrhoea to four hospitals in southern Botswana were eligible. Participants were assigned to treatment groups by web-based block randomisation. Test-and-treat results were not blinded, but participants and research staff were blinded to L. reuteri/placebo assignment; this was dosed as 1×108 cfu/mL by mouth daily and continued for 60 days. The primary outcome was 60-day age-standardised height (HAZ) adjusted for baseline HAZ. All analyses were by intention to treat. The trial was registered at Clinicaltrials.gov.ResultsRecruitment began on 12 June 2016 and continued until 24 October 2018. There were 66 participants randomised to the test-and-treat plus L. reuteri group, 68 randomised to the test-and-treat plus placebo group, 69 to the standard care plus L. reuteri group and 69 to the standard care plus placebo group. There was no demonstrable impact of the test-and-treat intervention (mean increase of 0.01 SD, 95% CI −0.14 to 0.16 SD) or the L. reuteri intervention (mean decrease of 0.07 SD, 95% CI −0.22 to 0.08 SD) on adjusted HAZ at 60 days.ConclusionsIn children hospitalised for acute gastroenteritis in Botswana, neither a test-and-treat algorithm targeting enteropathogens, nor a 60-day course of L. reuteri DSM 17938, were found to markedly impact linear growth or other important outcomes. We cannot exclude the possibility that test-and-treat will improve the care of children with significant enteropathogens (such as Shigella) in their stool.Trial registration numberNCT02803827.
44
Wadhwa, Arun, Dhanasekhar Kesavelu, Kishore Kumar, et al. "Role of Lactobacillus reuteri DSM 17938 on Crying Time Reduction in Infantile Colic and Its Impact on Maternal Depression: A Real-Life Clinic-Based Study." Clinics and Practice 12, no. 1 (2022): 37–45. http://dx.doi.org/10.3390/clinpract12010005.
Full textAbstract:
Background: Infantile colic is characterized by prolonged periods of inconsolable, incessant crying and persistent fussing in an otherwise healthy infant. It is a self-limiting condition, but causes significant stress to mothers. AIM: To observe the role of Lactobacillus reuteriDSM 17938 in reducing crying time in colicky infants in routine clinical practice. Methods: This was a prospective observational multicentric clinic-based study. Each practitioner included approximately 30 infants < 5 months of age with infantile colic who were prescribed L. reuteri DSM 17938 for a period of 21 days. There were four physical consultations and two telephonic consultations. The parents were given a daily diary to record the duration of crying and fussing episodes and a questionnaire was administered during the consultations. Results: A total of 120 infants with a mean age of 56.9 ± 34.2 days were included in this 28-day study. The mean crying time as reported by the parents in the subject diary reduced from 248.2 ± 101.2 min, 95% CI: 229.45, 266.94 at baseline to 45.6 ± 79.1 min 95% CI: 31.02, 60.31 at study end (P < 0.01). The clinical response (defined as reduction of 50% in crying time) was observed in 85% of subjects at study end. The fussiness and parental perception of colic recorded during the consultations were reduced by 66% and 72%, respectively, at study end. The maternal depression scores were reduced to 63% at study end. Conclusion: L. reuteri DSM 17938 was associated with a significant reduction in crying time in colicky infants, and showed improvement in maternal depression.
45
Jadrešin, Oleg, Iva Hojsak, Zrinjka Mišak, et al. "Lactobacillus reuteri DSM 17938 in the Treatment of Functional Abdominal Pain in Children." Journal of Pediatric Gastroenterology and Nutrition 64, no. 6 (2017): 925–29. http://dx.doi.org/10.1097/mpg.0000000000001478.
Full text
46
Dinleyici, Ener Cagri, Nazan Dalgic, Sirin Guven, et al. "Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting." Jornal de Pediatria (Versão em Português) 91, no. 4 (2015): 392–96. http://dx.doi.org/10.1016/j.jpedp.2015.05.008.
Full text
47
Dinleyici, Ener Cagri, Nazan Dalgic, Sirin Guven, et al. "Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting." Jornal de Pediatria 91, no. 4 (2015): 392–96. http://dx.doi.org/10.1016/j.jped.2014.10.009.
Full text
48
Butler, Éile, Christoffer Lundqvist, and Jakob Axelsson. "Lactobacillus reuteri DSM 17938 as a Novel Topical Cosmetic Ingredient: A Proof of Concept Clinical Study in Adults with Atopic Dermatitis." Microorganisms 8, no. 7 (2020): 1026. http://dx.doi.org/10.3390/microorganisms8071026.
Full textAbstract:
Atopic Dermatitis (AD) is a chronically relapsing skin condition characterized by dry, itchy, and inflamed skin where sufferers can frequently be subject to infections. Probiotics are known to be potent immune-modulators, and live Lactobacillus reuteri DSM 17938 has shown to be anti-inflammatory but also to possess antimicrobial and barrier function properties. This study aimed to investigate and compare two investigational ointment products (topical probiotic and control) for cutaneous acceptability, safety, and efficacy under normal conditions of use, in adult subjects with atopic dermatitis. The products were applied twice daily for 8 weeks, and cutaneous acceptability, SCORAD index, local SCORAD, and adverse events were evaluated after 4 and 8 weeks of treatment. At the end of the observations, it was demonstrated that both the probiotic-containing and probiotic-free ointments were both cutaneously acceptable and safe. It importantly showed a statistically and clinically significant improvement of the SCORAD index and local SCORAD in adult subjects with AD after 4 and 8 weeks of continuous use. In conclusion, we show evidence that the probiotic product, containing live L. reuteri DSM 17938 as an extra ingredient, is safe and promising as a novel topical cosmetic ointment and with further testing could be a standard topical product for the management of atopic dermatitis or other disorders associated with the skin.
49
Wongkaew, Malaiporn, Bow Tinpovong, Korawan Sringarm, et al. "Crude Pectic Oligosaccharide Recovery from Thai Chok Anan Mango Peel Using Pectinolytic Enzyme Hydrolysis." Foods 10, no. 3 (2021): 627. http://dx.doi.org/10.3390/foods10030627.
Full textAbstract:
Pectin recovered from mango peel biomass can be used as a potential source for pectic oligosaccharide hydrolysate with excellent probiotic growth-enhancing performance and prebiotic potentials. Consequently, the objectives of the current study were to optimise the enzyme hydrolysis treatment of mango peel pectin (MPP) and to evaluate the pectic oligosaccharide effects of Lactobacillus reuteri DSM 17938 and Bifidobacterium animalis TISTR 2195. Mango of “chok anan” variety was chosen due to its excessive volume of biomass in processing and high pectin content. The optimal treatment for mango peel pectic oligosaccharide (MPOS) valorisation was 24 h of fermentation with 0.3% (v/v) pectinase. This condition provided small oligosaccharides with the molecular weight of 643 Da that demonstrated the highest score of prebiotic activity for both of B. animalis TISTR 2195 (7.76) and L. reuteri DSM 17938 (6.87). The major sugar compositions of the oligosaccharide were fructose (24.41% (w/w)) and glucose (19.52% (w/w)). For the simulation of prebiotic fermentation, B. animalis TISTR 2195 showed higher proliferation in 4% (w/v) of MPOS supplemented (8.92 log CFU/mL) than that of L. reuteri (8.53 CFU/mL) at 72 h of the fermentation time. The main short chain fatty acids (SCFAs) derived from MPOS were acetic acid and propionic acid. The highest value of total SCFA was achieved from the 4% (w/v) MPOS supplementation for both of B. animalis (68.57 mM) and L. reuteri (69.15 mM). The result of this study therefore conclusively advises that MPOS is a novel pectic oligosaccharide resource providing the opportunity for the sustainable development approach through utilising by-products from the fruit industry.
50
Salvatore, Silvia, Mariagrazia Carlino, Simona Sestito, Daniela Concolino, Massimo Agosti, and Licia Pensabene. "Nutraceuticals and Pain Disorders of the Gut–Brain Interaction in Infants and Children: A Narrative Review and Practical Insights." Nutrients 16, no. 3 (2024): 349. http://dx.doi.org/10.3390/nu16030349.
Full textAbstract:
Different nutraceuticals are often considered by parents of infants and children with abdominal pain and disorders of the gut–brain interaction. Herb extracts and natural compounds have long been used in traditional medicine, but clinical pediatric trials are very limited. This narrative review based on relevant studies identified through a search of the literature in Pubmed and Medline updated to October 2023 focused on the effect of nutraceuticals in infantile colic, functional abdominal pain, and irritable bowel syndrome in children and adolescents. Significant reductions in colic episodes and crying time were reported in two studies on fennel (seeds oil or tea), in three studies on different multiple herbal extracts (all including fennel), in one study on Mentha piperita, and in at least two double-blind randomized controlled studies on Lactobacillus reuteri DSM 17938 and Bifidobacterium lactis BB-12 (108 CFU/day for at least 21 days) in breast-fed infants. Compared to a placebo, in children with functional abdominal pain or irritable bowel syndrome, a significant reduction in pain was reported in two studies supplementing peppermint oil capsules or psyllium fibers, and in one study on corn fiber cookies, partial hydrolyzed guar gum, a specific multiple herbal extract (STW-5), or vitamin D supplementation. To date, there is moderate-certainty evidence with a weak grade of recommendation on Lactobacillus reuteri DSM 17938 (108 CFU/day) in reducing pain intensity in children with functional abdominal pain and for Lactobacillus rhamnosus GG (1–3 × 109 CFU twice daily) in reducing pain frequency and intensity in children with IBS. Further large and well-designed pediatric studies are needed to prove the efficacy and safety of different herbal extracts and prolonged use of studied products in infants and children with pain disorders of the gut–brain interaction.